


Author Index

VOLUME 23, 2002

- Allen, James N., 127
- Bach, John R., 283
- Barsan, William, 1
- Baughman, Robert P., 503, 513, 543, 589
- Benditt, Joshua O., 231
- Berk, John L., 155
- Bernaciak, Jorge, 597
- Birnbaumer, Diane M., 3
- Blackwell, Thomas H., 11
- Bodí, M., 435
- Bonten, Marc J. M., 481
- Bradley, Deborah, 543
- Brooks, G. Daniel, 339
- Brun-Buisson, Christian, 457
- Celli, Bartolome, 275
- Chacon, Carolina, 597
- Courvalin, Patrice, 449
- Crémieux, Anne Claude, 449
- Curros, Marisela Luisa, 597
- Danzl, Daniel, 57
- Delgado, Joao H., 11
- Deng, Jane C., 513
- DePalo, Vera A., 201
- Díaz, E., 435
- Epstein, William L., 571
- Escowitz, Hal E., 47
- Fahy, John V., 361
- Falk, Jay L., 47
- Ford, Jean G., 369
- Gay, Peter C., 267
- Gilchrist, James M., 191
- Gomez, Hernan F., 11
- Guillemot, Didier, 449
- Guluma, Kama, 37
- Hamid, Qutabaya, 347
- Henig, Noreen R., 307
- Hill, Nicholas S., 189, 293
- Iqbal, Javed, 361
- Iregui, Manuel G., 489
- Israel, Elliot, 331
- Jarjour, Nizar J., 399
- Johnson, Simon R., 85
- Judson, Marc A., 529
- Kaufman, Adam H., 543
- Kavuru, Mani S., 115
- Keller, Michael B., 317
- King, Mark A., 127
- Kollef, Marin H., 489
- Kraft, Monica, 315
- Krawiec, Marzena, 399
- Leeper, Kenneth V., 415
- Lemanske, Robert F., 339
- Leung, Donald Y. M., 387
- Limper, Andrew H., 93
- Lowenstein, Steven R., 317
- Lower, Elyse E., 589
- Luna, Carlos M., 457
- Lynch, Joseph P., III, 513, 555
- Magro, Cynthia M., 127
- Maya, Gustavo, 597
- Mayer, Stephan A., 221
- Mazzzone, Peter, J., 115
- McCool, F. Dennis, 201
- McGowan, John E. Jr., 415
- Michet, Clement J., 145
- Mohsenin, Vahid, 248
- Morales, Ian J., 267
- Newton, Christopher R. H., 11
- Niederman, Michael S., 457
- O'Regan, Anthony, 155
- Parish, James M., 135
- Patel, Paresh J., 415
- Pelletier, Shawn J., 497
- Piper, Amanda, 211
- Pollack, Charles V. Jr., 3
- Prakash, Udaya B. S., 83, 103, 167
- Raffin, Thomas A., 307
- Raghu, Ganesh, 177
- Raymond, Daniel P., 497
- Raymond, Lawrence, 543
- Rello, J., 435
- Rochester, Carolyn L., 248
- Rosenow, Edward C., 135
- Rumbak, Mark J., 411, 427
- Sawyer, Robert G., 497
- Scott, Phillip, 69
- Sharma, Om P., 579
- Shill, Holly, 261
- Shorr, Andrew F., 555
- Simonds, Anita K., 231
- Sirgo, G., 435
- Skinner, Martha, 155
- Spahn, Joseph D., 377, 387
- Spina, Juan Carlos, 597
- Staats, Bruce A., 145
- Stacy, Mark, 261
- Sunmonu, Yisa, 369
- Szefer, Stanley J., 377, 387
- Tami, Thomas A., 549
- Tattersfield, Anne E., 85
- Teirstein, Alvin, 505
- Thomassen, Mary Jane, 115
- Tulic, Meri K., 347
- Utz, James P., 145
- Vassallo, Robert, 93
- Vaszar, Laszlo, 307
- Vaughan, William M., 489
- Venditti, Julio, 597
- Vucinic, Violeta, 579
- Waterer, Grant W., 443
- Wechsler, Michael E., 331
- Weinacker, Ann B., 307
- White, Suzanne R., 27
- Woodruff, Prescott G., 361
- Wunderink, Richard G., 443
- Wurfel, Mark M., 177
- Yavagal, Dileep R., 221
- Younger, John G., 1
- Zink, Brian, 37
- Zisman, David A., 555



Subject Index

VOLUME 23, 2002

- Abdominal adenopathy, gastrointestinal sarcoidosis and, 536-538
- Acid-base status, respiratory muscle evaluation in neuromuscular disorders and, 203-208
- Action potential duration (APD), hypothermia, emergency management protocols, 61-66
- Acute inflammatory demyelinating polyneuropathy (AIDP), pulmonary function and, 193-199
- Acute respiratory distress syndrome (ARDS), pneumonia complications, 443-447
- Adrenergic receptors, beta2-adrenergic agonists, asthma and, 369-374
- Air medical transport systems, emergency medical services (EMS), interfacility transport, 11-18
- Airway remodeling techniques, asthma management and, 361-366
- Allergic inflammation
- asthma and, 347-357
 - leukotriene receptor antagonists, asthma management with, 399-407
 - steroid-resistant asthma, 390-396
- Alveolar macrophages (AMs), pulmonary alveolar proteinosis (PAP), 119-123
- Amphetamine, toxicity, 27-34
- Amyloidosis
- pulmonary and tracheobronchial disease, diagnosis and management, 155-163
 - tracheobronchopathia osteochondroplastica, 167-173
- Amyotrophic lateral sclerosis (ALS)
- pulmonary function and, 191-199
 - respiratory complications, 239-246
- Angiomyolipoma, lymphangioleiomyomatosis (LAM), 85-91
- Antiarrhythmic therapy, cardiac sarcoidosis, 522-524
- Antibiotics
- antimicrobial resistance evolution and use of, 449-455
 - hospital-acquired pneumonia, treatment guidelines, 457-467
 - hospital-acquired pneumonia, utilization strategies for limiting antimicrobial resistance, 497-500
 - ventilator-associated pneumonia (VAP), natural history of resolution, 472-477
- Anticoagulants, ischemic stroke, emergency management, 69-79
- Anti-fibrinogen therapy, ischemic stroke, emergency management, 77-79
- Antimicrobial resistance
- antibiotic utilization strategies for limiting of, 497-500
 - evolution of, antibiotic use and, 449-455
 - hospital-acquired pneumonia, treatment guidelines, 457-467
 - ventilator-associated pneumonia (VAP), epidemiology and microbiology with antibiotic therapy, 415-423
 - ventilator-associated pneumonia (VAP), natural history of resolution, 471-477
- Antiplatelet therapy, ischemic stroke, emergency management, 69-79
- Arrhythmias, cardiac sarcoidosis, 515-524
- Arterial blood gases (ABGs)
- diaphragm paralysis, respiratory management and, 278-281
 - neuromuscular syndromes, pulmonary function testing and, 223-228
 - respiratory muscle evaluation in neuromuscular disorders and, 203-208
- Arthritis, musculoskeletal sarcoidosis and, 561-566
- Ascites, gastrointestinal sarcoidosis and, 536-538
- Aspiration syndromes
- acute respiratory distress syndrome (ARDS), pneumonia as complication of, 443-447
 - respiratory complications of Parkinson's disease and, 264
 - stroke and respiratory complications and, 248-258
 - ventilator-associated pneumonia (VAP), head injured and severe trauma patients, 435-440
 - ventilator-associated pneumonia (VAP), pathogenesis, 427-431
- Aspirin-induced asthma, leukotriene receptor antagonists, management with, 402-407
- Asthma
- airway remodeling, 361-366
 - beta2-adrenergic agonists and, 369-374
 - distal lung physiology and, 347-357
 - epidemiology, 317-327
 - genetics of, 331-337
 - infectious disease and, 339-343
 - leukotriene receptor antagonists, 399-407
 - management overview, 315-316
 - steroid inhalants and, 377-384
 - steroid-unresponsive syndromes, 387-396
- Autoimmune disorders, pulmonary alveolar proteinosis (PAP), 115-123
- Azathioprine, extrapulmonary sarcoidosis and, 589-594
- Bacterial resistance. *See* Antimicrobial resistance
- Barotrauma
- air emergency medical services (EMS), interfacility transport, 13-18

- Barotrauma (*cont.*)
 neuromuscular disease and spinal cord injury,
 noninvasive IPPV and, 287-291
- Basement membranes, airway remodeling techniques, asthma
 management and, 362-366
- Becker muscular dystrophy (BMD), respiratory
 complications, 231-238
- Berger's disease, renal sarcoidosis, 582-586
- Beta2-adrenergic agonists, asthma and, 369-374
- Beta-agonist receptor gene, asthma genetics, 335-337
- Beta receptor antagonist. *See also* Beta2-adrenergic agonists
 overdose management, pharmacological principles, 19-24
- Blau's syndrome, sarcoidosis and, 545-547
- Bone metabolism, musculoskeletal sarcoidosis and, 555,
 565-566
- Brachial plexitis, pulmonary function and, 193-199
- Brain injury, emergency management, 37-44
- Breathing evaluation
 sleep disruption and neuromuscular disease, 216-218
 stroke and respiratory complications and, 248-258
- Bronchoalveolar lavage (BAL)
 eosinophilic pneumonia, diagnosis and management,
 127-133
 pulmonary alveolar microlithiasis, 110-111
 steroid-resistant asthma, 387-396
- Bronchoscopy
 pulmonary Langerhans' cell histiocytosis (PLCH),
 97-100
 tracheobronchopathia osteochondroplastica diagnosis,
 167-173
- Budd-Chiari syndrome, hepatic sarcoidosis and, 530-538
- Bullard/Woo laryngoscopes, difficult airway intubation,
 troubleshooting and management, 6-8
- Burn injuries, ventilator-associated pneumonia (VAP), risk
 factors for, 439-440
- Calcification, pulmonary alveolar microlithiasis, 103-111
- Calcium channel blockers, overdose management,
 pharmacological principles, 19-24
- Calcium metabolism, kidney sarcoidosis and, 579-586
- Candidate gene research, asthma genetics, 331-337
- Cardiac transplantation, cardiac sarcoidosis, 524
- Cardiopulmonary bypass (CPB), hypothermia, emergency
 management protocols, 65-66
- Cardiovascular system
 amphetamine toxicity, 27-34
 hypothermia, emergency management protocols, 59-66
 muscular dystrophy, cardiomyopathy and respiratory
 complications, 234-238
 sarcoidosis, diagnosis and management, 513-524
 submersion injury management, 51-53
- Cartilage damage
 relapsing polychondritis, diagnosis and management,
 145-152
 tracheobronchopathia osteochondroplastica, 167-173
- Catecholamines, calcium channel blockers and beta receptor
 antagonist overdose management, pharmacological
 principles, 23-24
- CD45+ cells, asthma pathophysiology and, 347-357
- Cerebral oxygen extraction, traumatic brain injury (TBI),
 37-44
- Cerebral perfusion pressure optimization, traumatic brain
 injury (TBI) management, 42-44
- Charcot-Leyden crystals, eosinophilic pneumonia diagnosis
 and management, 127-133
- Chest radiography, pulmonary Langerhans' cell histiocytosis
 (PLCH), 97-100
- Chest wall rigidity, respiratory complications of Parkinson's
 disease and, 261-264
- Chondritis, relapsing polychondritis, diagnosis and
 management, 145-152
- Chronic cholestasis syndrome, hepatic sarcoidosis and, 530-538
- Cirrhosis, hepatic sarcoidosis and, 530-538
- Clinical pulmonary infection score (CPIS)
 hospital-acquired pneumonia, treatment guidelines,
 459-467
 ventilator-associated pneumonia (VAP), natural history
 of resolution, 471-477
- Collagen, airway remodeling techniques, asthma
 management and, 361-366
- Combitube device, difficult airway intubation,
 troubleshooting and management, 7-8
- Computed tomography (CT)
 mediastinal granuloma/mediastinal fibrosis, differential
 diagnosis, 135-142
 relapsing polychondritis, diagnosis and management,
 150-152
- Confirmation devices, difficult airway intubation,
 troubleshooting and management, 7-8
- Congenital myopathies
 muscular dystrophy, respiratory complications, 234-238
 pulmonary function and, 198-199
- Conjunctival inflammation, sarcoidosis and, 545-547
- Consolidated Omnibus Budget Reconciliation Act
 (COBRA), emergency medical services (EMS),
 interfacility transport, 16-18
- Contiguous pathogenesis, ventilator-associated pneumonia
 (VAP), 431
- Continuous arteriovenous rewarming (CAVR), hypothermia,
 emergency management protocols, 65-66
- Continuous positive airway pressure (CPAP)
 hypothermia, emergency management protocols, 64-66
 relapsing polychondritis, diagnosis and management,
 150-152
- Core rewarming, hypothermia, emergency management
 protocols, 57-66
- Co-resistance, antibiotic use and evolution of antimicrobial
 resistance, 449-455
- Corticosteroids
 asthma and steroid inhalants, 377-384
 cardiac sarcoidosis therapy, 521-524
 extrapulmonary sarcoidosis and, 589-594
- Cranial nerves, sarcoidosis, diagnosis and management,
 506-511
- Cricothyrotomy, difficult airway, troubleshooting and
 management, 3-8
- Cross-resistance, antibiotic use and evolution of antimicrobial
 resistance, 449-455
- Cutaneous sarcoidosis, diagnosis and management, 571-576
- Cytokines
 asthma and, 347-357
 steroid-resistant asthma, 387-396

- Deep vein thrombosis, stroke and respiratory complications and, 253-258
- Diaphragm paralysis, respiratory management, 275-281
- Diaphragm ultrasound, respiratory muscle evaluation in neuromuscular disorders and, 201-208
- Diffuse calcispherytes, pulmonary alveolar microlithiasis, 103-111
- Diphosphonate lung scan, pulmonary alveolar microlithiasis, 103-111
- Distal airways, asthma and, 347-357
- Dopaminergic neurons, respiratory complications of Parkinson's disease and, 261-264
- Dose-response curves, inhaled corticosteroids, asthma and, 377-384
- Drowning, emergency management protocols, 47-53
- Drug abuse. *See also* Overdose management
amphetamine toxicity, 27-34
- Duchenne muscular dystrophy (DMD), respiratory complications, 231-238
- Dysphagia, stroke and respiratory complications and, 248-258
- Early-onset pneumonia, hospital-acquired pneumonia, treatment guidelines, 460-467
- Ecstasy. *See* 3,4-Methylene-dioxymethamphetamine (MDMA)
- Electrolyte imbalance, amphetamine toxicity, 32-34
- Emergency Medical Treatment and Active Labor Act (EMTALA), emergency medical services (EMS), interfacility transport, 16-18
- Emergency management
acute ischemic stroke, 69-79
airway troubleshooting, 3-8
amphetamine toxicity, 27-34
calcium and beta receptor antagonist overdoses, 19-24
critical care medicine, 1
hypothermia, 57-66
interfacility transports, 11-18
submersion injuries, 47-53
traumatic brain injury, 37-44
- Emery-Dreifuss muscular dystrophy, respiratory complications, 231-238
- End-of-life care, neuromuscular disease, long-term management issues, 307-313
- Endotracheal intubation, difficult airway, troubleshooting and management, 3-8
- Environmental factors
asthma, 317-327
pulmonary fibrosis, 180-184
- Eosinophilic pneumonia, diagnosis and management, 127-133
- Eosinophils, asthma pathophysiology and, 347-357
- Ephedrine, toxicity, 27-34
- Epithelial cells, airway remodeling techniques, asthma management and, 362-366
- Equipment and supplies, emergency medical services (EMS), interfacility transport, 14-18
- Ethics, neuromuscular disease management, 307-313
- Exercise-induced bronchoconstriction (EIB), leukotriene receptor antagonists, management with, 402-407
- Expiratory flow rates, respiratory muscle evaluation in neuromuscular disorders and, 203-208
- Extracorporeal membrane oxygenation (ECMO), emergency medical services (EMS), interfacility transport, 17-18
- Extrapulmonary sarcoidosis, diagnosis and management, 589-594
- Extrathoracic sarcoidosis, case study, 597-600
- Facioscapulohumeral muscular dystrophy, respiratory complications, 235-238
- Familial hypocalciuric hypercalcemia (FHH), pulmonary fibrosis, 183-184
- Fiberoptic intubation, difficult airway, troubleshooting and management, 5-8
- Fibroproliferation
pneumonia complication of acute respiratory distress syndrome (ARDS), 443-447
pulmonary fibrosis, 177-184
- Fibrosing mediastinitis, mediastinal granuloma/mediastinal fibrosis, 135-142
- Formulary restriction protocols, antibiotic utilization strategies for limiting of antimicrobial resistance, 499-500
- Gastric aspiration, ventilator-associated pneumonia (VAP), pathogenesis, 427-431
- Gastrointestinal tract
amphetamine toxicity and function of, 32-34
sarcoidosis and involvement of, 529-538
ventilator-associated pneumonia prevention, oral and gastrointestinal tract decontamination, 481-486
- Gaucher's disease, pulmonary fibrosis, 182
- Genetic studies
asthma, 317-327, 331-337
beta2-adrenergic agonists, asthma epidemiology and, 372-374
pulmonary fibrosis, 177-184
- Glomerulonephritis, renal sarcoidosis, 581-586
- Glossopharyngeal breathing, neuromuscular disease and spinal cord injury, noninvasive IPPV and, 289-291
- Glucagon, calcium channel blockers and beta receptor antagonist overdose management, pharmacological principles, 23-24
- Glucocorticoids
inhaled corticosteroids, asthma and, 377-384
steroid-resistant asthma, 387-396
- Goblet cells, airway remodeling techniques, asthma management and, 361-366
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), pulmonary alveolar proteinosis (PAP), 115-123
- Granulomatous myositis, musculoskeletal sarcoidosis and, 560-566
- Granulomatous nephritis, kidney sarcoidosis, 579-586
- Granulomatous vasculitis, renal sarcoidosis, 582-583
- Ground transportation systems, emergency medical services (EMS), interfacility transport, 11-18
- Guillain-Barré syndrome, respiratory complications, 221-228
- Gum bougies, difficult airway intubation, troubleshooting and management, 6-8
- Hand washing protocols, hospital-acquired pneumonia (HAP), nonpharmacological intervention, 489-493

- Head injury patients, ventilator-associated pneumonia and, 435-440
- Heat balance, hypothermia, emergency management protocols, 57-66
- Heerfordt's disease
ocular sarcoidosis and, 545-547
sinonasal sarcoidosis and, 549-553
- Hematogenous pathogenesis, ventilator-associated pneumonia (VAP), 431
- Heparan sulfate proteoglycan (HSP), amyloidosis diagnosis and management, 163
- Hepatic sarcoidosis, diagnosis and management, 529-538
- Hermansky-Pudlak syndrome, pulmonary fibrosis, 181
- High-resolution computed tomography (HRCT), asthma pathophysiology and, 356-357
- Histoplasmosis, mediastinal granuloma/mediastinal fibrosis, 135-142
- Hormone therapy, lymphangioleiomyomatosis (LAM), 90-91
- Hospital-acquired pneumonia (HAP)
antibiotic utilization, strategies for limiting antimicrobial resistance, 497-500
epidemiology and microbiology, 415-423
nonpharmacological intervention, 489-493
preventive strategies, oral and gastrointestinal tract decontamination, 481-486
treatment guidelines, 457-467
- Hydroxychloroquine, extrapulmonary sarcoidosis and, 589-594
- Hypercalcemia, kidney sarcoidosis, 579-586
- Hypercalciuria, kidney sarcoidosis, 579-586
- Hyperinsulinemic euglycemia (HIE), calcium channel blockers and beta receptor antagonist overdose management, pharmacological principles, 23-24
- Hyperresponsiveness
asthma epidemiology, 317-327
beta2-adrenergic agonists, asthma epidemiology and, 370-374
- Hyperthyroidism, thyroid sarcoidosis and, 580-586
- Hypertonic saline, traumatic brain injury (TBI) management, 41-44
- Hyperventilation, traumatic brain injury (TBI) management, 41-44
- Hypotension, traumatic brain injury (TBI), 38-44
- Hypothermia, emergency management protocols, 57-66
- Hypothyroidism, thyroid sarcoidosis and, 580-586
- Hypoventilation, REM hypoventilation, neuromuscular disease and, 211-218
- Hypoxia, traumatic brain injury (TBI), 38-44
- Idiopathic pulmonary fibrosis (IPF), pulmonary fibrosis, 181-184
- IgA nephropathy, renal sarcoidosis, 582-586
- Immunoglobulin light-chain (AL) amyloidosis, diagnosis and management, 155-163
- Immunotherapy
neuromuscular disease, pulmonary function testing and criteria for, 225-228
neuromuscular syndromes, pulmonary function testing and, 225-228
- Incidence studies
asthma epidemiology, 317-327
beta2-adrenergic agonists, asthma epidemiology and, 370-374
hospital-acquired pneumonia (HAP), epidemiology and microbiology, 415-423
- Infectious disease
asthma and, 339-343
submersion injury management, 51-53
- Infliximab, extrapulmonary sarcoidosis and, 589-594
- Inhaled corticosteroids, asthma and, 377-384
- Inotropic agents, calcium channel blockers and beta receptor antagonist overdose management, pharmacological principles, 23-24
- Intensive care unit (ICU)
antibiotic utilization strategies for limiting of antimicrobial resistance, 497-500
hospital-acquired pneumonia, nonpharmacological intervention, 489-493
hospital-acquired pneumonia, treatment guidelines, 457-467
submersion injury management protocols, 47-53
ventilator-associated pneumonia, preventive strategies, oral and gastrointestinal tract decontamination, 481-486
ventilator-associated pneumonia (VAP), epidemiology and microbiology, 415-423
ventilator-associated pneumonia (VAP), natural history of resolution, 471-477
- Interfacility transport, emergency medical services (EMS), 11-18
- Interleukins, steroid-resistant asthma, 387-396
- Interstitial lung disease
lymphangioleiomyomatosis (LAM), 85-91
pulmonary fibrosis, 177-184
- Intraaortic balloon counterpulsation (IABC), emergency medical services (EMS), interfacility transport, 17-18
- Intraaortic balloon pump (IABP), calcium channel blockers and beta receptor antagonist overdose management, pharmacological principles, 24
- Intracranial hemorrhage (ICH), ischemic stroke, emergency management, 75-79
- Intracranial pressure (ICP)
ischemic stroke, emergency management, 75-79
submersion injury management, 51-53
traumatic brain injury (TBI), 37-44
- Intracranial sarcoidosis, diagnosis and management, 506-511
- Intravenous immunoglobulin (IVIG) therapy, neuromuscular syndromes, pulmonary function testing and, 223-228
- Intubation techniques
endotracheal intubation, difficult airway, troubleshooting and management, 3-8
hospital-acquired pneumonia, nonpharmacological intervention, 490-493
neuromuscular disease
indications, 302-304
pulmonary function testing and criteria for, 223-228
- Ischemic stroke, emergency management, 69-79
- Kidney sarcoidosis. *See* Renal sarcoidosis
- β -Lactamases, antimicrobial resistance evolution, inhibitor development, 451-455

- Laryngeal mask airway, troubleshooting and management, 3-8
- Laser capture microdissection, asthma pathophysiology and, 357
- Late-onset pneumonia, hospital-acquired pneumonia, treatment guidelines, 460-467
- Legal issues
- emergency medical services (EMS), interfacility transport, 16-18
 - neuromuscular disease, long-term management ethics, 307-313
- Leukotriene receptor antagonists, asthma management, 399-407
- Levodopa, respiratory complications of Parkinson's disease and, 261-264
- Lighted stylet technique, difficult airway intubation, troubleshooting and management, 6-8
- Limb-girdle muscular dystrophy (LMG), respiratory complications, 234-238
- 5-Lipoxygenase promoter gene (5-LO), asthma genetics, 335-337
- Liver, sarcoidosis and involvement of, 529-538
- Lower respiratory tract infection (LRTI), hospital-acquired pneumonia, treatment guidelines, 457-467
- Lung biopsy, pulmonary Langerhans' cell histiocytosis (PLCH), 97-100
- Lung disease management
- eosinophilic pneumonias, 127-133
 - lymphangioleiomyomatosis, 85-91
 - mediastinal granuloma and fibrosis, 135-142
 - pulmonary alveolar microlithiasis (PAM), 103-111
 - pulmonary alveolar proteinosis (PAP), 115-123
 - pulmonary fibrosis genetics, 177-184
 - pulmonary Langerhans' cell histiocytosis (PLCH), 93-100
 - pulmonary tracheobronchial amyloidosis, 155-163
 - rare/orphan diseases, 83-84
 - relapsing polychondritis (RP), 145-152
 - tracheobronchopathia osteochondroplastica, 167-173
- Lung transplantation, lymphangioleiomyomatosis (LAM), 91
- Lymphangioleiomyomatosis (LAM)
- pathophysiology and management, 85-91
 - pulmonary fibrosis, 182-184
- Macrolides, lincosamides, and streptogramins (MLS), antimicrobial resistance evolution and use of, 450-455
- Mannitol, traumatic brain injury (TBI) management, 41-44
- Maximal inspiratory/expiratory pressures, respiratory muscle evaluation in neuromuscular disorders and, 204-208
- Maximal sniff pressures, respiratory muscle evaluation in neuromuscular disorders and, 204-208
- Mechanical circulatory support, emergency medical services (EMS), interfacility transport, 17-18
- Mechanical ventilation
- neuromuscular disease, 302-304
 - ventilator-associated pneumonia (VAP), epidemiology and microbiology, 415-423
 - ventilator-associated pneumonia (VAP), natural history of resolution, 472-477
 - ventilator-associated pneumonia (VAP), nonpharmacological intervention, 489-493
 - ventilator-associated pneumonia (VAP), pathogenesis, 427-431
- Mediastinal granuloma/mediastinal fibrosis, diagnosis and management, 135-142
- Metabolic imbalance, amphetamine toxicity, 32-34
- Metabolic myopathies, pulmonary function and, 198-199
- Methamphetamine, toxicity, 27-34
- Methicillin-sensitive *Staphylococcus aureus* (MSSA)
- antimicrobial resistance evolution and, 452-455
 - ventilator-associated pneumonia (VAP), 435-440
- Methotrexate, extrapulmonary sarcoidosis and, 589-594
- 3,4-Methylene-dioxymethamphetamine (MDMA), toxicity, 27-34
- Microbial superantigens, steroid-resistant asthma, 392-396
- Micronodules and microliths, pulmonary alveolar microlithiasis, 103-111
- Morbidity studies
- asthma, 317-327
 - beta2-adrenergic agonists, asthma epidemiology and, 372-374
 - cardiac sarcoidosis, 521-524
 - hospital-acquired pneumonia (HAP), epidemiology and microbiology, 415-423
 - pneumonia complication of acute respiratory distress syndrome (ARDS), 443-447
 - ventilator-associated pneumonia (VAP), natural history of resolution, 472-477
- Motor neuron disease. *See* Amyotrophic lateral sclerosis (ALS)
- Multiple sclerosis, respiratory system complications, 267-273
- Muscular dystrophies
- pulmonary function and, 191-199
 - respiratory complications, 231-238
- Musculoskeletal system
- amphetamine toxicity, 32-34
 - sarcoidosis, 555-566
- Myasthenia gravis
- pulmonary function and, 191-199
 - respiratory complications, 221-228
- Myopathy
- muscular dystrophy, cardiomyopathy and respiratory complications, 234-238
 - musculoskeletal sarcoidosis, 555-566
 - pulmonary function and, 191-199
 - sarcoidosis, diagnosis and management, 507-511
- Myositis, musculoskeletal sarcoidosis and, 559-566
- Myotonic dystrophy, respiratory complications, 234-238
- Nasal inflammation, sinonasal sarcoidosis and, 549-553
- Near drowning. *See* Submersion injury
- Nephritis, kidney sarcoidosis, 579-586
- Neurochemistry, traumatic brain injury (TBI), 38-44
- Neurofibromatosis, pulmonary fibrosis, 182-184
- Neurogenic pulmonary edema, stroke and respiratory complications and, 257-258
- Neurological system
- amphetamine toxicity, 27-34
 - hypothermia, emergency management protocols, 61-66
 - submersion injury management, 51-53
- Neuromuscular disorders
- amyotrophic lateral sclerosis, respiratory complications, 239-246

Neuromuscular disorders (*cont.*)

- continuous noninvasive ventilation, 283-291
- diaphragm paralysis, respiratory management, 275-281
- Guillain-Barré syndrome and myasthenia gravis, respiratory complications, 221-228
- long-term management, ethical issues, 307-313
- muscular dystrophy, respiratory complications, 231-238
- Parkinson's disease, respiratory complications, 261-264
- poliomyelitis and multiple sclerosis, respiratory complications, 267-273
- pulmonary function, overview, 191-199
- respiratory complications, 189-190
- respiratory muscle evaluation, 201-208
- sarcoidosis, diagnosis and management, 505-511
- sleep abnormalities, 211-218
- stroke, respiratory complications, 248-258
- ventilator management, 293-304
- Neuromuscular junction (NMJ) diseases, pulmonary function and, 194-199
- Neuronal death, traumatic brain injury (TBI), 37-44
- Neuropathy, pulmonary function and, 191-199
- Neutrophilia, steroid-resistant asthma, 392-396
- Niemann-Pick disease, pulmonary fibrosis, 181-182
- Nitric oxide, emergency medical services (EMS), interfacility transport, 17-18
- Nocturnal respiratory failure, neuromuscular disease and, 211-218
- Noninvasive positive pressure ventilation (NPPV)
 - amyotrophic lateral sclerosis, respiratory complications and, 239-246
 - difficult airway, troubleshooting and management, 3-8
 - muscular dystrophy, respiratory complications, 231-238
 - neuromuscular disease, 283-291, 296-304
 - spinal cord injury, 283-291
- Nonsteroidal anti-inflammatory drugs (NSAIDs), relapsing polychondritis, diagnosis and management, 150-152
- Nosocomial infection. *See* Hospital-acquired pneumonia (HAP)
- Obstructive sleep apnea
 - neuromuscular disease and, 211-218
 - respiratory complications of Parkinson's disease and, 263-264
 - respiratory system complications, 267-273
 - stroke and respiratory complications and, 251-258
- Oculatory system, sarcoidosis and involvement of, 543-547
- Optic neuropathy, sarcoidosis and, 545-547
- Oropharyngeal colonization
 - pneumonia complication of acute respiratory distress syndrome (ARDS), 443-447
 - ventilator-associated pneumonia prevention, oral and gastrointestinal tract decontamination, 481-486
 - ventilator-associated pneumonia (VAP), pathogenesis, 427-431
- Orphan diseases
 - eosinophilic pneumonias, 127-133
 - lymphangioleiomyomatosis (LAM), 85-91
 - mediastinal granuloma and fibrosis, 135-142
 - pulmonary alveolar microlithiasis (PAM), 103-111
 - pulmonary alveolar proteinosis (PAP), 115-123
 - pulmonary fibrosis genetics, 177-184
 - pulmonary Langerhans' cell histiocytosis (PLCH), 93-100

- pulmonary tracheobronchial amyloidosis, 155-163
- rare/orphan diseases, 83-84
- relapsing polychondritis (RP), 145-152
- tracheobronchopathia osteochondroplastica, 167-173
- Osseous sarcoidosis, diagnosis and management, 562-566
- Overdose management. *See also* Drug abuse
 - calcium channel blockers and beta receptor antagonist, pharmacological principles, 19-24
- Palliative care ethics
 - amyotrophic lateral sclerosis, respiratory complications and, 245-246
 - neuromuscular disease, long-term management issues, 307-313
- Pancreas, sarcoidosis and involvement of, 536-538
- Paranasal sinus disease, sinonasal sarcoidosis and, 549-553
- Parenchyma, asthma and, 347-357
- Parkinson's disease, respiratory complications of, 261-264
- Patient care issues, emergency medical services (EMS), interfacility transport, 15-18
- Patient positioning protocols, hospital-acquired pneumonia, nonpharmacological intervention, 490-493
- Pediatric patients
 - neuromuscular disease, ventilation management for, 302-304
 - submersion injury in, 47-53
- Peripheral neuropathies
 - pulmonary function and, 193-199
 - sarcoidosis, diagnosis and management, 507-511
- Peritoneal sarcoidosis, case study, 597-600
- Personnel issues, emergency medical services (EMS), interfacility transport, 14-18
- Pharmacokinetics
 - asthma genetics and, 331-337
 - beta2-adrenergic agonists, asthma and, 369-374
 - hospital-acquired pneumonia, treatment guidelines, 466-467
- Phrenic nerve stimulation, respiratory muscle evaluation in neuromuscular disorders and, 201-208
- Plasmapheresis, Guillain-Barré syndrome, pulmonary function and, 225-228
- Pleuropulmonary fibrosis, respiratory complications of Parkinson's disease and, 263-264
- Pneumonia
 - acute respiratory distress syndrome (ARDS) and, 443-447
 - amyotrophic lateral sclerosis, respiratory complications and risk of, 242-246
 - antimicrobial resistance
 - antibiotic use and evolution of, 449-455
 - utilization strategies for limiting of, 497-500
 - eosinophilic pneumonia, 127-133
 - head-injured and severe trauma patients, 435-440
 - hospital-acquired pneumonia (HAP)
 - epidemiology and microbiology, 415-423
 - nonpharmacological prevention, 489-493
 - overview, 411-413
 - preventive strategies, 481-486
 - therapeutic resolution, 471-477
 - treatment guidelines, 457-467
 - respiratory complications of Parkinson's disease and, 264
 - ventilator-associated pneumonia (VAP), pathogenesis, 427-431

- Poliomyelitis, respiratory system complications, 267-273
- Portal hypertension, hepatic sarcoidosis and, 530-538
- Positive end-expiratory pressure (PEEP), Guillain-Barré syndrome, pulmonary function and, 225-228
- Postpolio syndrome (PPS), respiratory system complications, 267-273
- Preventive strategies
- hospital-acquired pneumonia (HAP)
 - nonpharmacological intervention, 489-493
 - oral and gastrointestinal tract decontamination, 481-486
 - ventilator-associated pneumonia (VAP), head injured and severe trauma patients, 435-440
- Prognostic indicators, submersion injury emergency management, 52-53
- Pseudomonas aeruginosa*, ventilator-associated pneumonia (VAP), natural history of resolution, 471-477
- Psychiatric effects, amphetamine toxicity, 32-34
- Pulmonary alveolar microlithiasis (PAM), diagnosis and management, 103-111
- Pulmonary alveolar proteinosis (PAP), diagnosis and management, 115-123
- Pulmonary embolism, stroke and respiratory complications and, 253-258
- Pulmonary fibrosis, genetics of, 177-184
- Pulmonary function testing. *See also* Lung disease management
- amphetamine toxicity, 32-34
 - Guillain-Barré syndrome and myasthenia gravis, 221-228
 - neuromuscular disorders, 191-199
 - relapsing polychondritis, diagnosis and management, 145-152
 - sleep disruption and neuromuscular disease and, 211-218
- Pulmonary infiltrates with eosinophilia (PIE) syndromes, eosinophilic pneumonia, diagnosis and management, 127-133
- Pulmonary Langerhans' cell histiocytosis (PLCH), diagnosis, pathogenesis, and management, 93-100
- Quinolones, antimicrobial resistance evolution and use of, 450-455
- Radiographic imaging
- amyloidosis diagnosis and management, 158-163
 - cardiac sarcoidosis, 516-524
 - mediastinal granuloma/mediastinal fibrosis, differential diagnosis, 135-142
- Rapid sequence intubation (RSI), difficult airway, troubleshooting and management, 3-8
- Recombinant tissue plasminogen activator (rt-PA), ischemic stroke, emergency management, 69-79
- Relapsing polychondritis, diagnosis and management, 145-152
- Renal cell carcinoma, renal sarcoidosis, 582-583
- Renal failure
- amphetamine toxicity, 33-34
 - hypothermia, emergency management protocols, 61-66
- Renal sarcoidosis, diagnosis and management, 579-586
- Respiratory syncytial virus (RSV), asthma and, 339-343
- Respiratory system
- amyotrophic lateral sclerosis (ALS) and complications of, 239-246
 - diaphragm paralysis, respiratory management, 275-281
 - extrapulmonary sarcoidosis, 589-594
 - failure, ventilator management criteria, 294-304
 - Guillain-Barré syndrome and complications of, 221-228
 - hypothermia, emergency management protocols, 59-66
 - muscular dystrophies and complications of, 231-238
 - myasthenia gravis and complications of, 221-228
 - neuromuscular disorders and, 189-190
 - Parkinson's disease and complications of, 261-264
 - poliomyelitis and multiple sclerosis and complications of, 267-273
 - respiratory muscle evaluation, neuromuscular disorders and, 201-208
 - stroke and complications of, 248-258
 - submersion injury emergency management, 50-53
 - ventilator-associated pneumonia (VAP), pathogenesis, 427-431
- Rhabdomyolysis, amphetamine toxicity, 32-34
- Rigid spine syndrome, respiratory complications, 235-238
- Risk factors
- asthma epidemiology, 317-327
 - hospital-acquired pneumonia (HAP), epidemiology and microbiology, 415-423
 - ventilator-associated pneumonia (VAP), head injured and severe trauma patients, 435-440
 - ventilator-associated pneumonia (VAP), natural history of resolution, 472-477
- Rotation strategies, antibiotic rotation for limiting of antimicrobial resistance, 499-500
- Sarcoidosis
- cardiac involvement in, 513-524
 - cutaneous sarcoidosis, 571-576
 - extrapulmonary sarcoidosis, therapeutic management, 589-594
 - hepatic, splenic, and gastrointestinal involvement, 529-538
 - musculoskeletal system, 555-566
 - neuromuscular, diagnosis and management review, 505-511
 - ocular manifestations, 543-547
 - overview, 503
 - peritoneal sarcoidosis case study, 597-600
 - sinonasal sarcoidosis, diagnosis and management, 549-553
 - thyroid and kidney involvement and calcium metabolism, 579-586
- Scleritis, sarcoidosis and, 545-547
- Sclerosis-associated disease, pulmonary fibrosis, 181-184
- Seizure prophylaxis, traumatic brain injury (TBI) management, 43-44
- Selective decontamination of the digestive tract (SDD), ventilator-associated pneumonia, preventive strategies, oral and gastrointestinal tract decontamination, 481-486
- Serum amyloid A (SAA) protein, amyloidosis diagnosis and management, 156-163
- Serum amyloid P (SAP) protein, amyloidosis diagnosis and management, 163
- Sinonasal sarcoidosis, diagnosis and management, 549-553
- Sinusitis, ventilator-associated pneumonia (VAP), pathogenesis, 427-431

- Skin diseases, cutaneous sarcoidosis, 571-576
- Sleep disruption
- neuromuscular disease, pulmonary function and, 211-218
 - poliomyelitis and multiple sclerosis, respiratory complications and, 267-273
 - respiratory complications of Parkinson's disease and, 263-264
 - stroke and respiratory complications and, 248-258
- Smoking, pulmonary Langerhans' cell histiocytosis (PLCH), 93-100
- Smooth muscle proliferation
- airway remodeling techniques, asthma management and, 361-366
 - lymphangioliomyomatosis (LAM), 85-91
- Socioeconomic conditions, asthma epidemiology, 317-327
- Spinal cord, sarcoidosis, diagnosis and management, 507-511
- Spinal cord injury, continuous noninvasive ventilation and, 283-291
- Spinal muscular atrophy (SMA)
- noninvasive IPPV and, 290-291
 - respiratory complications, 231-238
- Spleen, sarcoidosis and involvement of, 529-538
- Steroid-resistant asthma, pathophysiology of, 387-396
- Stroke. *See also* Ischemic stroke
- respiratory complications, 248-258
- Submersion injury. *See also* Drowning
- emergency management protocols, 47-53
- Submucosal glands, airway remodeling techniques, asthma management and, 365-366
- Superior vena cava obstruction, mediastinal granuloma/mediastinal fibrosis, 135-142
- Surfactant phospholipids, pulmonary alveolar proteinosis (PAP), 115-123
- Tarragona prevention strategy, ventilator-associated pneumonia (VAP), head injured and severe trauma patients, 439-440
- T-cells, steroid-resistant asthma, 387-396
- Technetium-99m scan, pulmonary alveolar microlithiasis, 103-111
- Thalidomide, extrapulmonary sarcoidosis and, 589-594
- T-helper 2 cytokines, asthma and, 347-357
- Therapeutic strategies
- antimicrobial resistance, antibiotic utilization for limiting of, 497-500
 - antimicrobial resistance evolution and antibiotic use, 452-455
 - hospital-acquired pneumonia (HAP), 457-467
 - hospital-acquired pneumonia (HAP), nonpharmacological intervention, 490-493
- Thermoregulation, amphetamine toxicity, 31-34
- Thrombolytic therapy, ischemic stroke, emergency management, 69-79
- Thyroid sarcoidosis, diagnosis and management, 579-586
- Total lung capacity (TLC), respiratory muscle evaluation in neuromuscular disorders and, 201-208
- Tracheal stenosis, relapsing polychondritis, diagnosis and management, 145-152
- Tracheobronchial amyloidosis, diagnosis and management, 155-163
- Tracheobronchopathia osteochondroplastica (TPO), diagnosis and management, 167-173
- Tracheostomy
- neuromuscular disease, pulmonary function testing and criteria for, 225-228
 - relapsing polychondritis, diagnosis and management, 150-152
- Transportation systems, emergency medical services (EMS), interfacility transport, 11-18
- Transthyretin (TTR) hereditary amyloidosis, diagnosis and management, 156-163
- Trauma patients, ventilator-associated pneumonia (VAP), 435-440
- Traumatic brain injury (TBI), emergency management, 37-44
- Tuberculosis, peritoneal sarcoidosis, differential diagnosis, case study, 597-600
- Tuberous sclerosis complex (TSC)
- lymphangioliomyomatosis (LAM), 85-91
 - pulmonary fibrosis, 182-184
- Tumor necrosis factor (TNF), extrapulmonary sarcoidosis and, 589-594
- Upper airway obstruction, respiratory complications of Parkinson's disease and, 261-264
- Uveitis, sarcoidosis and, 544-547
- Venous thromboembolism, stroke and respiratory complications and, 253-258
- Ventilator-associated pneumonia (VAP)
- acute respiratory distress syndrome (ARDS) and, 443-447
 - epidemiology and microbiology, 415-423
 - head injured and severe trauma patients, 435-440
 - natural history of resolution, 471-477
 - nonpharmacological intervention, 489-493
 - pathogenesis, 427-431
 - preventive strategies, oral and gastrointestinal tract decontamination, 481-486
- Ventilator management
- amyotrophic lateral sclerosis, respiratory complications and, 239-246
 - long-term neuromuscular disease, ethical issues, 307-313
 - neuromuscular disease, 283-291, 293-304
 - pulmonary function testing and criteria for, 224-228
 - spinal cord injury, 283-291
- Ventricular assist device (VAD), emergency medical services (EMS), interfacility transport, 17-18
- Vital capacity (VC), respiratory muscle evaluation in neuromuscular disorders and, 201-208
- Weather, emergency medical services (EMS), interfacility transport, 11-18
- Werdnig-Hoffman disease, respiratory complications, 236-238
- Whole lung lavage (WLL), pulmonary alveolar proteinosis (PAP), 122-123

